|
gptkbp:instanceOf
|
gptkb:chemical_compound
recreational drug
stimulant
|
|
gptkbp:abusePotential
|
high
|
|
gptkbp:ATCCode
|
gptkb:N06BA01
|
|
gptkbp:brand
|
gptkb:Adzenys_XR-ODT
gptkb:Dynavel_XR
gptkb:Evekeo
Benzedrine (historical)
|
|
gptkbp:CASNumber
|
300-62-9
|
|
gptkbp:category
|
amphetamine
stimulant
monoamine alkaloid
psychostimulant
|
|
gptkbp:chemicalFormula
|
C9H13N
|
|
gptkbp:discoveredBy
|
gptkb:Lazăr_Edeleanu
|
|
gptkbp:discoveredIn
|
1887
|
|
gptkbp:eliminationHalfLife
|
9-14 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasEnantiomers
|
gptkb:dextroamphetamine
gptkb:levoamphetamine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Amphetamine
|
|
gptkbp:isRacemicMixture
|
yes
|
|
gptkbp:IUPACName
|
1-phenylpropan-2-amine
|
|
gptkbp:legalStatus
|
gptkb:Schedule_II_(Australia)
Schedule I (Canada)
Schedule II controlled substance (US)
Class B drug (UK)
|
|
gptkbp:mainStreet
|
speed
bennies
pep pills
uppers
|
|
gptkbp:marketedAs
|
1930s
|
|
gptkbp:mechanismOfAction
|
increases synaptic concentrations of dopamine and norepinephrine
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
135.21 g/mol
|
|
gptkbp:overdoseSymptoms
|
gptkb:arrhythmia
death
coma
seizures
hyperthermia
hallucinations
agitation
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:PubChem_CID
|
3007
CHEMBL405
DB00182
|
|
gptkbp:relatedCompounds
|
gptkb:dextroamphetamine
gptkb:levoamphetamine
gptkb:methylphenidate
amphetamine
|
|
gptkbp:routeOfAdministration
|
oral
inhalation
intravenous
intranasal
|
|
gptkbp:sideEffect
|
addiction
anxiety
hypertension
loss of appetite
increased heart rate
insomnia
dry mouth
|
|
gptkbp:UNII
|
U3C9PE4U90
|
|
gptkbp:uses
|
treatment of ADHD
treatment of narcolepsy
|
|
gptkbp:bfsParent
|
gptkb:Smino
|
|
gptkbp:bfsLayer
|
5
|